NEW YORK—Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, has announced the appointment of Andrew Jones as chief financial officer. Jones brings more than 30 years of diverse finance and accounting leadership experience to the position, spanning therapeutics and medical technology/devices, according to the announcement. Most recently, Jones served as chief financial officer of NovaBay Pharmaceuticals, Inc., a commercial stage ophthalmic company. Eyenovia’s current CFO, John Gandolfo, is retiring and will remain with the company through November to help ensure a smooth transition, the company said.

“We are very pleased to welcome Andrew to the Eyenovia team and believe that his diverse and relevant experience is a perfect fit for our company at this crucial stage,” said Michael Rowe, chief executive officer of Eyenovia. “As we approach a critical data readout for MicroPine later this year, the U.S. launch of clobetasol, as well as the continued commercial ramp of Mydcombi, we will rely on Andrew’s track record of success—in both operations as well as capital raising—to ensure that we are best positioned for long-term success.

“Additionally, on behalf of the entire Eyenovia team, I would like to thank John Gandolfo for his many contributions since joining the company in 2017. We have made tremendous progress during that time, and I wish him well in his retirement,” Rowe said.

Prior to joining NovaBay, Jones served as vice president of finance at MyoScience, Inc., a company that successfully developed and commercialized a pain management device through its acquisition by Pacira BioSciences, Inc. Jones previously served as controller for various public and private life sciences companies including Armetheon, Inc., Asante Solutions, Inc. and Genelabs Technologies, Inc., and he began his career with PricewaterhouseCoopers.

“Eyenovia’s commercial strategy is rapidly advancing, with two FDA-approved products and a third in late Phase 3 development, in addition to several collaboration agreements that have the potential to further advance and expand the use of its already proven Optejet technology to address additional large market ophthalmic indications,” said Jones. “With many opportunities to drive long-term growth and value creation, I am excited to join the Eyenovia team as it works to be a leader in the development of highly differentiated topical ophthalmic medications.”